http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Press+Releases/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html <p align="justify">CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.</p> <p align="justify"><strong>Fireside Chat Details: </strong><br/>Time: 2:40-3:00 PM ET<br/>Date: Wednesday, May 20, 2026</p> <p align="justify">Investors http://www.streetinsider.com/Globe+Newswire/Reviva+to+Participate+in+Fireside+Chat+at+A.G.P.%E2%80%99s+Annual+Healthcare+Company+Showcase/26510515.html Mon, 18 May 2026 08:00:00 -0400 A.50216777 O.38695651 O.54516537 RVPH http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502725.html si-local-file:///var/storage/secattach/20260515/26502725.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502725.html Fri, 15 May 2026 12:21:00 -0400 O.38695651 RVPH http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502725.html si-local-file:///var/storage/secattach/20260515/26502725.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502725.html Fri, 15 May 2026 12:21:00 -0400 O.38695651 RVPH http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26497499.html si-local-file:///var/storage/secattach/20260514/26497499.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26497499.html Thu, 14 May 2026 21:26:00 -0400 O.38695651 RVPH http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26497499.html si-local-file:///var/storage/secattach/20260514/26497499.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++REVIVA+PHARMACEUTICALS+++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26497499.html Thu, 14 May 2026 21:26:00 -0400 O.38695651 RVPH http://www.streetinsider.com/Earnings/Reviva+Pharmaceuticals+Holdings%2C+Inc.+%28RVPH%29+Misses+Q1+EPS+by+41c/26487481.html <p>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported Q1 EPS of ($0.46), $0.41 worse than the analyst estimate of ($0.05).</p><p>For earnings history and earnings-related data on Reviva Pharmaceuticals Holdings, Inc. (RVPH) <a href="http://www.streetinsider.com/ec_earnings.php?q=RVPH">click here</a>.</p> http://www.streetinsider.com/Earnings/Reviva+Pharmaceuticals+Holdings%2C+Inc.+%28RVPH%29+Misses+Q1+EPS+by+41c/26487481.html Wed, 13 May 2026 17:14:03 -0400 RVPH http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++REVIVA+PHARMACEUTICALS++++For%3A+Mar+31/26487024.html si-local-file:///var/storage/secattach/20260513/26487024.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++REVIVA+PHARMACEUTICALS++++For%3A+Mar+31/26487024.html Wed, 13 May 2026 16:44:00 -0400 O.38695651 RVPH http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++REVIVA+PHARMACEUTICALS++++For%3A+Mar+31/26487024.html si-local-file:///var/storage/secattach/20260513/26487024.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++REVIVA+PHARMACEUTICALS++++For%3A+Mar+31/26487024.html Wed, 13 May 2026 16:44:00 -0400 O.38695651 RVPH http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVIVA+PHARMACEUTICALS++++For%3A+May+13/26486987.html si-local-file:///var/storage/secattach/20260513/26486987.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVIVA+PHARMACEUTICALS++++For%3A+May+13/26486987.html Wed, 13 May 2026 16:41:00 -0400 O.38695651 RVPH http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVIVA+PHARMACEUTICALS++++For%3A+May+13/26486987.html si-local-file:///var/storage/secattach/20260513/26486987.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++REVIVA+PHARMACEUTICALS++++For%3A+May+13/26486987.html Wed, 13 May 2026 16:41:00 -0400 O.38695651 RVPH http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Press+Releases/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Globe+Newswire/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Globe+Newswire/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH http://www.streetinsider.com/Globe+Newswire/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html <p align="center"><em>- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - <br/></em><em>- FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -<br/></em><em>- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -</em></p> <p align="justify">CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the http://www.streetinsider.com/Globe+Newswire/Reviva+Reports+First+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26486848.html Wed, 13 May 2026 16:35:00 -0400 A.06822034 A.50216777 O.20026344 O.38695651 O.54516537 RVPH